Subject
Management, Monitoring, Policy and Law,Geography, Planning and Development
Reference17 articles.
1. 1. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-5. [Crossref]
2. 2. Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bögemann M, et al. Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging 2018; 45: 860-77. [Crossref]
3. 3. Haffner MC, Laimer J, Chaux A, Schäfer G, Obrist P, Brunner A, et al. High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol 2012; 25: 1079-85. [Crossref]
4. 4. Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging 2017; 44: 1614-21. [Crossref]
5. 5. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO Classification of Head and Neck Tumours. International Agency for Research on Cancer. Accessed January 23, 2017. https://www.iarc.who.int/news-events/who-classification-of-head-and-neck-tumours/ [Crossref]